After a lull in mergers and acquisitions activity, Big Pharma could begin to use its cash stores to buy out smaller targets, potentially fueling the momentum in biotechnology-related exchange traded funds that target the small and mid cap segments.

VIEW ARTICLE
If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.